Cargando…

Risk of bias assessment of sequence generation: a study of 100 systematic reviews of trials

BACKGROUND: Systematic reviews of randomised trials guide policy and healthcare decisions. Yet, we observed that some reviews judge randomised trials as high or unclear risk of bias (ROB) for sequence generation, potentially introducing bias. However, to date, the extent of this issue has not been w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wuytack, Francesca, Regan, Maria, Biesty, Linda, Meskell, Pauline, Lutomski, Jennifer E., O’Donnell, Martin, Treweek, Shaun, Devane, Declan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323681/
https://www.ncbi.nlm.nih.gov/pubmed/30621793
http://dx.doi.org/10.1186/s13643-018-0924-1
_version_ 1783385812624211968
author Wuytack, Francesca
Regan, Maria
Biesty, Linda
Meskell, Pauline
Lutomski, Jennifer E.
O’Donnell, Martin
Treweek, Shaun
Devane, Declan
author_facet Wuytack, Francesca
Regan, Maria
Biesty, Linda
Meskell, Pauline
Lutomski, Jennifer E.
O’Donnell, Martin
Treweek, Shaun
Devane, Declan
author_sort Wuytack, Francesca
collection PubMed
description BACKGROUND: Systematic reviews of randomised trials guide policy and healthcare decisions. Yet, we observed that some reviews judge randomised trials as high or unclear risk of bias (ROB) for sequence generation, potentially introducing bias. However, to date, the extent of this issue has not been well examined. We evaluated the consistency in the ROB assessment for sequence generation of randomised trials in Cochrane and non-Cochrane reviews, and explored the reviewers’ judgement of the quality of evidence for the related outcomes. METHODS: Cochrane intervention reviews (01/01/2017–31/03/2017) were retrieved from the Cochrane Database of Systematic Reviews. We also searched for systematic reviews in ten general medical journals with highest impact factors (01/01/2016–31/03/2017). We examined the proportion of reviews that rated the sequence generation domain as high, low or unclear risk of selection bias. For reviews that had rated any randomised trials as high or unclear risk of bias, we examined the proportion that had assessed the quality of evidence. RESULTS: Overall, 100 systematic reviews were included in our analysis. We evaluated 64 Cochrane reviews which comprised of 984 randomised trials; 0.8% (n = 8) and 52.2% (n = 514) were rated as high and unclear ROB for sequence generation respectively. We further evaluated 36 non-Cochrane reviews which comprised of 1376 trials; 5.8% (n = 80) and 39.6% (n = 545) were rated as high and unclear ROB respectively. Ninety percent (n = 10) of non-Cochrane reviews which rated randomised trials as high ROB for sequence generation did not report an underlying reason. All Cochrane reviews assessed the quality of evidence (GRADE). For the non-Cochrane reviews, only just over half had assessed the quality of evidence. CONCLUSION: Systematic reviews of interventions frequently rate randomised trials as high or unclear ROB for sequence generation. In general, Cochrane reviews were more transparent than non-Cochrane reviews in ROB and quality of evidence assessment. The scientific community should more strongly promote consistent ROB assessment for sequence generation to minimise selection bias and support transparent quality of evidence assessment. Consistency ensures that appropriate conclusions are drawn from the data.
format Online
Article
Text
id pubmed-6323681
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63236812019-01-10 Risk of bias assessment of sequence generation: a study of 100 systematic reviews of trials Wuytack, Francesca Regan, Maria Biesty, Linda Meskell, Pauline Lutomski, Jennifer E. O’Donnell, Martin Treweek, Shaun Devane, Declan Syst Rev Research BACKGROUND: Systematic reviews of randomised trials guide policy and healthcare decisions. Yet, we observed that some reviews judge randomised trials as high or unclear risk of bias (ROB) for sequence generation, potentially introducing bias. However, to date, the extent of this issue has not been well examined. We evaluated the consistency in the ROB assessment for sequence generation of randomised trials in Cochrane and non-Cochrane reviews, and explored the reviewers’ judgement of the quality of evidence for the related outcomes. METHODS: Cochrane intervention reviews (01/01/2017–31/03/2017) were retrieved from the Cochrane Database of Systematic Reviews. We also searched for systematic reviews in ten general medical journals with highest impact factors (01/01/2016–31/03/2017). We examined the proportion of reviews that rated the sequence generation domain as high, low or unclear risk of selection bias. For reviews that had rated any randomised trials as high or unclear risk of bias, we examined the proportion that had assessed the quality of evidence. RESULTS: Overall, 100 systematic reviews were included in our analysis. We evaluated 64 Cochrane reviews which comprised of 984 randomised trials; 0.8% (n = 8) and 52.2% (n = 514) were rated as high and unclear ROB for sequence generation respectively. We further evaluated 36 non-Cochrane reviews which comprised of 1376 trials; 5.8% (n = 80) and 39.6% (n = 545) were rated as high and unclear ROB respectively. Ninety percent (n = 10) of non-Cochrane reviews which rated randomised trials as high ROB for sequence generation did not report an underlying reason. All Cochrane reviews assessed the quality of evidence (GRADE). For the non-Cochrane reviews, only just over half had assessed the quality of evidence. CONCLUSION: Systematic reviews of interventions frequently rate randomised trials as high or unclear ROB for sequence generation. In general, Cochrane reviews were more transparent than non-Cochrane reviews in ROB and quality of evidence assessment. The scientific community should more strongly promote consistent ROB assessment for sequence generation to minimise selection bias and support transparent quality of evidence assessment. Consistency ensures that appropriate conclusions are drawn from the data. BioMed Central 2019-01-08 /pmc/articles/PMC6323681/ /pubmed/30621793 http://dx.doi.org/10.1186/s13643-018-0924-1 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Wuytack, Francesca
Regan, Maria
Biesty, Linda
Meskell, Pauline
Lutomski, Jennifer E.
O’Donnell, Martin
Treweek, Shaun
Devane, Declan
Risk of bias assessment of sequence generation: a study of 100 systematic reviews of trials
title Risk of bias assessment of sequence generation: a study of 100 systematic reviews of trials
title_full Risk of bias assessment of sequence generation: a study of 100 systematic reviews of trials
title_fullStr Risk of bias assessment of sequence generation: a study of 100 systematic reviews of trials
title_full_unstemmed Risk of bias assessment of sequence generation: a study of 100 systematic reviews of trials
title_short Risk of bias assessment of sequence generation: a study of 100 systematic reviews of trials
title_sort risk of bias assessment of sequence generation: a study of 100 systematic reviews of trials
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323681/
https://www.ncbi.nlm.nih.gov/pubmed/30621793
http://dx.doi.org/10.1186/s13643-018-0924-1
work_keys_str_mv AT wuytackfrancesca riskofbiasassessmentofsequencegenerationastudyof100systematicreviewsoftrials
AT reganmaria riskofbiasassessmentofsequencegenerationastudyof100systematicreviewsoftrials
AT biestylinda riskofbiasassessmentofsequencegenerationastudyof100systematicreviewsoftrials
AT meskellpauline riskofbiasassessmentofsequencegenerationastudyof100systematicreviewsoftrials
AT lutomskijennifere riskofbiasassessmentofsequencegenerationastudyof100systematicreviewsoftrials
AT odonnellmartin riskofbiasassessmentofsequencegenerationastudyof100systematicreviewsoftrials
AT treweekshaun riskofbiasassessmentofsequencegenerationastudyof100systematicreviewsoftrials
AT devanedeclan riskofbiasassessmentofsequencegenerationastudyof100systematicreviewsoftrials